Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$86.75

0.54 (0.63%)

, IONS

Ionis Pharmaceuticals

$48.76

1.28 (2.70%)

18:24
10/07/18
10/07
18:24
10/07/18
18:24

Alnylam's Onpattro highly efficacious, safer than competitor, says Piper Jaffray

Piper Jaffray analyst Edward Tenthoff notes that Ionis Pharmaceuticals (IONS) announced FDA approval of TEGSEDI for treatment of hATTR polyneuropathy. The analyst also points out that the label includes a Black Box warning for thrombocytopenia and glomerulonephritis requiring every 2-week monitoring, and will be marketed by Ionis subsidiary Akcea (AKCA) with a Risk Evaluation and Mitigation Strategy. TEGSEDI is administered subcutaneously every week versus Alnylam's (ANLY) ONPATTRO intravenously every 3 weeks with steroids, he adds. Tenthoff believes that ONPATTRO appears safer and highly efficacious, and should win out. The analyst reiterates an Overweight rating and $160 price target on Alnylam shares.

ALNY

Alnylam

$86.75

0.54 (0.63%)

IONS

Ionis Pharmaceuticals

$48.76

1.28 (2.70%)

AKCA

Akcea Therapeutics

$31.85

1.24 (4.05%)

  • 23

    Oct

  • 27

    Nov

ALNY Alnylam
$86.75

0.54 (0.63%)

09/24/18
PIPR
09/24/18
NO CHANGE
Target $50
PIPR
Neutral
Ionis platelet issue now appears removed, says Piper Jaffray
The most important takeaway from Ionis Pharmaceuticals' APO(a)-LRx results this morning is that there appears to be no platelet issue associated with the LICA technology, Piper Jaffray analyst Tyler Van Buren tells investors in a research note titled "These LICA Results Are A Big Deal - Platelet Issue Now Appears Removed." As it relates to Tegsedi specifically, the analyst says that while the product's subcutaneous dosing provides a clear competitive advantage to Alnylam's (ALNY) Onpattro infusion regimen, many view it as being offset by the need for bi-weekly platelet monitoring. However, Van Buren now believes that the need for platelet monitoring is definitively removed with Ionis' LICA technology. He believes this morning's results provide significant long-term validation for Ionis' LICA technology platform. The analyst keeps a Neutral rating on Ionis Pharmaceuticals with a $50 price target.
09/27/18
PIPR
09/27/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam weakness on safety concerns a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff attributes the initial weakness today in shares of Alnylam Pharmaceuticals to safety concerns from the interim Phase III givosiran data in acute hepatic porphyrias. Safety was consistent with prior Phase I data showing no additional deaths or cases of pancreatitis, five serious adverse events were due to underlying disease and one discontinuation for liver transaminase elevation resolved, Tenthoff tells investors in a research note. The analyst says he's a buyer of Alnylam due to the unmet medical need in acute hepatic porphyrias. Tenthoff reiterates an Overweight rating on Alnylam with a $160 price target. The stock is down 1%, or $1.12, to $90.21 in early trading.
09/28/18
PIPR
09/28/18
NO CHANGE
Target $160
PIPR
Overweight
Piper says Alnylam making transition to commercial play on orphan diseases
After Alnylam announced an NDA filing on Onpattro for hATTR Amyloidosis in Japan, Piper Jaffray analyst Edward Tenthoff said the company is transitioning toward being a commercial play on orphan diseases. The analyst, who forecasts 2018 Onpattro sales of $10.7M growing to $81M in 2019, keeps an Overweight and $160 price target on Alnylam shares.
10/01/18
CANT
10/01/18
INITIATION
Target $135
CANT
Overweight
Alnylam initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Alnylam Pharmaceuticals with an Overweight rating and $135 price target.
IONS Ionis Pharmaceuticals
$48.76

1.28 (2.70%)

08/28/18
STFL
08/28/18
NO CHANGE
STFL
Hold
CRL for Waylivra 'somewhat of a surprise,' says Stifel
Stifel analyst Paul Matteis said the complete response letter for Ionis Pharmaceuticals (IONS) and Akcea Therapeutics' (AKCA) Waylivra was "somewhat of a surprise" given the positive advisory committee decision, though he also noted that "safety was acutely in focus" during the committee meeting. The basis of the CRL is not yet known and Akcea was "close to the vest" on its nature, leading Matteis to remove Waylivra from his valuations for the two stocks. Doing that lowered his Akcea price target to $25 from $33 and cut his Ionis target to $45 from $47. However, he thinks the main investor question will be regarding read-through to Tegsedi and Matteis' assumption for its approval remains unchanged, he added. The analyst keeps Hold ratings on Ionis and Akcea shares, which are down 12.5% and 29%, respectively, in pre-market trading.
09/18/18
NEED
09/18/18
INITIATION
Target $45
NEED
Buy
Akcea Therapeutics initiated with a Buy at Needham
Needham analyst Chad Messer initiated Akcea Therapeutics (AKCA) with a Buy rating and a price target of $45, saying it is an "attractive" way for investors to leverage "decades of innovation" by the parent Ionis Pharma (IONS) through ownership of its most advanced-stage programs. The analyst cites the unfolding "breakthrough" in the approval of a new class of antisense drugs which "directly block protein synthesis in cells by binding to RNA". Messer adds that Akcea is positioned for near-term commercial opportunity for its Tegsedi and Waylivra programs.
10/03/18
MSCO
10/03/18
NO CHANGE
Target $45
MSCO
Equal Weight
Ionis most likely gets Tegsedi approval with black box, says Morgan Stanley
Morgan Stanley analyst David Lebowitz laid out three potential scenarios for the upcoming FDA approval decision about Ionis Pharmaceuticals' Tegsedi, which is scheduled to come on or before October 6. If the FDA were to issue a complete response letter, or CRL, and prevent on-time launch, Lebowitz sees greater than 20% downside for the shares, though he puts the probability of this occurring at 40%. If Tegsedi is approved with a black box safety warning, which he sees as the most likely scenario with odds he pegs at 45%, Lebowitz sees the stock trading up or down about 5%. If Tegsedi is approved with a "clean" label it would lead to a steeper ramp in revenue and Lebowitz sees 20% or more upside to the stock in this scenario, though he puts the odds at just 15%. He maintains an Equal Weight rating on Ionis shares ahead of the PDUFA with a $45 price target.
AKCA Akcea Therapeutics
$31.85

1.24 (4.05%)

08/28/18
HCWC
08/28/18
NO CHANGE
HCWC
Neutral
Ionis CRL for Waylivra raises questions on Tegsedi approval, says JPMorgan
Ionis Pharmaceuticals (IONS) announced last night that its subsidiary Akcea Therapeutics (AKCA) received a complete response letter for Waylivra from the FDA. JPMorgan analyst Jessica Fye says she had a chance to catch up with management but that they did not provide much in the way of details regarding the CRL. Given that Waylivra and Tegsedi are both generation 2.5 products and both have had platelet safety issues, the market will naturally question if the risk of a CRL also extends to Tegsedi, Fye tells investors in a research note. The analyst expects Ionis shares to reflect greater risk to approval for Tegsedi as well as Waylivra. She notes that Waylivra is worth $2 per share in her model for Ionis while Tegsedi contributes greater than $10 per share. The stock in premarket trading is down 12%, or $6.68, to $47.02. Fye keeps a Neutral rating on Ionis Pharmaceuticals.
08/28/18
RILY
08/28/18
NO CHANGE
Target $230
RILY
Buy
Ionis CRL positive for Alnylam's Onpattro, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar believes the complete response letter for Ionis Pharmaceuticals' (IONS) and Akcea Therapeutics' (AKCA) Waylivra is positive for Alnylam Pharmaceuticals' (ALNY) Onpattro. The analyst reiterates a Buy rating on Alnylam with a $230 price target.

TODAY'S FREE FLY STORIES

02:55
02/20/19
02/20
02:55
02/20/19
02:55
General news
FX Update: The Dollar has traded mostly firmer »

FX Update: The Dollar…

01:55
02/20/19
02/20
01:55
02/20/19
01:55
General news
Asian Market Wrap: »

Asian Market Wrap:…

LUV

Southwest

$57.66

0.02 (0.03%)

21:49
02/19/19
02/19
21:49
02/19/19
21:49
Downgrade
Southwest rating change at Goldman Sachs »

Southwest downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

RARE

Ultragenyx

$56.80

0.14 (0.25%)

21:17
02/19/19
02/19
21:17
02/19/19
21:17
Recommendations
Ultragenyx analyst commentary at Piper Jaffray »

Piper Jaffray positive on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

21:05
02/19/19
02/19
21:05
02/19/19
21:05
General news
Japan's exports fell 8.4% in January »

Japan's exports fell…

PANW

Palo Alto Networks

$230.19

3.46 (1.53%)

20:49
02/19/19
02/19
20:49
02/19/19
20:49
Downgrade
Palo Alto Networks rating change at Gabelli »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 25

    Feb

  • 26

    Feb

  • 04

    Mar

  • 05

    Mar

AROC

Archrock

$10.06

0.365 (3.76%)

20:33
02/19/19
02/19
20:33
02/19/19
20:33
Earnings
Archrock sees FY19 net income $73M-$103M vs. $29.2M in FY18 »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CTL

CenturyLink

$14.10

0.37 (2.69%)

20:32
02/19/19
02/19
20:32
02/19/19
20:32
Downgrade
CenturyLink rating change at RBC Capital »

CenturyLink downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 11

    Mar

TTD

Trade Desk

$161.76

3.69 (2.33%)

20:31
02/19/19
02/19
20:31
02/19/19
20:31
Downgrade
Trade Desk rating change at Stifel »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

CVS

CVS Health

$69.92

0.39 (0.56%)

, SO

Southern Company

$48.91

0.35 (0.72%)

20:25
02/19/19
02/19
20:25
02/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CVS

CVS Health

$69.92

0.39 (0.56%)

SO

Southern Company

$48.91

0.35 (0.72%)

ADI

Analog Devices

$104.21

-1.49 (-1.41%)

HSIC

Henry Schein

$63.11

0.73 (1.17%)

OC

Owens Corning

$55.38

0.73 (1.34%)

WIX

Wix.com

$125.70

4.31 (3.55%)

WWW

Wolverine World Wide

$39.50

-0.04 (-0.10%)

CNDT

Conduent

$14.52

0.93 (6.84%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 09

    Apr

  • 28

    May

AROC

Archrock

$10.06

0.365 (3.76%)

20:21
02/19/19
02/19
20:21
02/19/19
20:21
Earnings
Archrock reports Q4 EPS 10c, consensus 8c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AI

Arlington Asset Investment

$8.70

-0.14 (-1.58%)

20:09
02/19/19
02/19
20:09
02/19/19
20:09
Syndicate
Arlington Asset Investment 6M share Spot Secondary priced at $8.33 »

Arlington Asset announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

GLD

SPDR Gold Shares

$126.70

1.89 (1.51%)

19:46
02/19/19
02/19
19:46
02/19/19
19:46
Hot Stocks
SPDR Gold Shares holdings fall to 792.45MT from 793.03MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$305.56

-2.2 (-0.71%)

19:17
02/19/19
02/19
19:17
02/19/19
19:17
Hot Stocks
Tesla CEO says company will make about 500,000 cars in 2019 »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

IDCC

InterDigital

$73.13

-0.26 (-0.35%)

19:06
02/19/19
02/19
19:06
02/19/19
19:06
Hot Stocks
InterDigital says LG Electronics extends license to use Hillcrest's Freespace »

InterDigital, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

TWTR

Twitter

$31.64

0.41 (1.31%)

19:03
02/19/19
02/19
19:03
02/19/19
19:03
Hot Stocks
Tesla CEO says 4,000 cars loading in San Francisco for Europe »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

OSPN

OneSpan

$16.78

0.645 (4.00%)

, HSTM

HealthStream

$26.95

0.09 (0.34%)

19:01
02/19/19
02/19
19:01
02/19/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

OSPN

OneSpan

$16.78

0.645 (4.00%)

HSTM

HealthStream

$26.95

0.09 (0.34%)

LNTH

Lantheus

$19.18

0.67 (3.62%)

CDNS

Cadence Design

$52.65

0.09 (0.17%)

CRMT

America's Car-Mart

$81.74

-0.43 (-0.52%)

DVN

Devon Energy

$28.31

-0.11 (-0.39%)

LMAT

LeMaitre

$25.09

-0.01 (-0.04%)

FIVN

Five9

$54.31

0.1 (0.18%)

NVTA

Invitae

$16.49

0.43 (2.68%)

LZB

La-Z-Boy

$32.23

0.845 (2.69%)

DK

Delek US

$34.87

0.025 (0.07%)

VRSK

Verisk Analytics

$124.45

-0.93 (-0.74%)

WIRE

Encore Wire

$56.32

1.32 (2.40%)

HLF

Herbalife Nutrition

$57.46

0.8 (1.41%)

TVTY

Tivity Health

$21.67

0.28 (1.31%)

IIN

IntriCon

$29.43

2 (7.29%)

LC

LendingClub

$3.62

0.05 (1.40%)

CXO

Concho Resources

$120.95

-2.03 (-1.65%)

FANG

Diamondback Energy

$104.75

-0.78 (-0.74%)

TXRH

Texas Roadhouse

$65.58

0.03 (0.05%)

SSTI

ShotSpotter

$48.18

2.2 (4.78%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 04

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 28

    Mar

  • 22

    May

  • 28

    May

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:58
02/19/19
02/19
18:58
02/19/19
18:58
Hot Stocks
Hudbay Minerals announces increased reserves at Lalor mine »

Hudbay Minerals announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:56
02/19/19
02/19
18:56
02/19/19
18:56
Hot Stocks
Hudbay Minerals reports Q4 copper output 37.2K tonnes, down 14% from last year »

Reports Q4 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CLXT

Calyxt

$13.56

0.15 (1.12%)

18:55
02/19/19
02/19
18:55
02/19/19
18:55
Hot Stocks
Calyxt, Agtegra Cooperative announce strategic collaboration »

Calyxt and Agtegra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:54
02/19/19
02/19
18:54
02/19/19
18:54
Earnings
Hudbay Minerals reports Q4 EPS (1c), consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOC

Northrop Grumman

$287.36

0.44 (0.15%)

18:39
02/19/19
02/19
18:39
02/19/19
18:39
Hot Stocks
Northrop Grumman recommends shareholders to reject offer by TRC Capital »

Northrop Grumman has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

18:31
02/19/19
02/19
18:31
02/19/19
18:31
Periodicals
POTUS says U.S. corn sales to China part of trade talks, Bloomberg says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$9.69

0.11 (1.15%)

18:29
02/19/19
02/19
18:29
02/19/19
18:29
Hot Stocks
Aphria announces early termination of Liberty Health Sciences divestment »

Aphria announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$18.01

0.02 (0.11%)

, AGN

Allergan

$137.94

-1.13 (-0.81%)

18:26
02/19/19
02/19
18:26
02/19/19
18:26
Hot Stocks
Teva finalizes settlement with FTC to resolve all outstanding litigation »

Teva Pharmaceutical…

TEVA

Teva

$18.01

0.02 (0.11%)

AGN

Allergan

$137.94

-1.13 (-0.81%)

ABBV

AbbVie

$80.50

-0.35 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 18

    May

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.